Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/telmisartan - THPharm

Drug Profile

Dapagliflozin/telmisartan - THPharm

Alternative Names: Telmisartan/dapagliflozin - THPharm; THP-001; THP-00101/THP-00102; THP-00102/THP-00101

Latest Information Update: 08 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator THPharm
  • Class Antihyperglycaemics; Antihypertensives; Benzhydryl compounds; Benzimidazoles; Benzoates; Chlorobenzenes; Glucosides; Heart failure therapies; Obesity therapies; Pyrans; Small molecules; Urologics
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypertension; Type 2 diabetes mellitus

Most Recent Events

  • 09 Nov 2023 THPharm completes a phase-I trial in Hypertension and Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT06063109)
  • 12 Oct 2023 THPharm plans to launch dapagliflozin/telmisartan in 2027
  • 09 Oct 2023 Phase-I clinical trials in Hypertension (In volunteers) in South Korea (PO) (NCT06063109)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top